Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 7, 2006; 12(25): 4038-4043
Published online Jul 7, 2006. doi: 10.3748/wjg.v12.i25.4038
Table 2 Anti-HBV DNA production (mean ± SD)
Treatment groupSerum HBV DNA (copies/mL)
0 wk4 wk8 wk12 wk16 wk
Group 1 normal diet recipients (n = 9)1.35E05 ± 3.64E041.34 E05 ± 3.20 E041.53 E05 ± 3.10 E041.30 E05 ± 2.43 E042.59 E05 ± 9.37 E04
Group 2 lamivudine recipients (n = 9)1.20 E05 ± 2.54 E045.52 E04 ± 1.63 E04b2.48 E04 ± 8.12E03b,d1.34 E04 ± 4.48 E03b,d1.12 E05 ± 2.70 E04
Group 3 Sp recipients (n = 9)1.73 E05 ± 4.69 E048.39 E04 ± 4.32 E044.07 E04 ± 1.63 E04a,d1.19 E04 ± 7.53 E03b,d1.91 E05 ± 6.87 E04